INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy

Mise à jour : Il y a 4 ans
Référence : NCT00153088

Femme et Homme

  • | Pays :
  • Japan
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The aim of this study is to compare the preventive effect of Telmisartan(Micardis) versus placebo control on the transition to overt nephropathy in patients with diabetic nephropathy manifesting microalbuminuria associated with type II diabetes, and to evaluate the efficacy and safety of Telmisart (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) for diabetic nephropathy patients.


Critère d'inclusion

  • Diabetic Nephropathies

Liens